Overview

Double-Blind, Randomized, Placebo-Controlled Study of Low Dose Oral Interferon Alfa-n3 (Human Leukocyte Derived) in ARC Patients

Status:
Completed

Trial end date:
1969-12-31

Target enrollment:

Participant gender:

Summary

To conduct a parallel-group, double-blind, randomized, placebo-controlled study to evaluate the safety and efficacy of an orally administered low dose interferon alfa-n3 as an immunomodulator in the treatment of mild to moderate symptomatic HIV+, AIDS-related complex (ARC) patients.

Phase:

N/A

Details

Lead Sponsor:

Interferon Sciences

Treatments:

Interferon-alpha
Interferons